Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
- Percentage of Patients With Complete Clearing of Corneal Staining at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]Percentage of patients with complete clearing of corneal staining at month 12. Corneal staining is evaluated following administration of fluorescein dye into the eye. Complete clearing is defined as the absence of corneal staining.
- Schirmer's Test at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]Schirmer's test at month 12. The Schirmer's tear test is performed on the eye with or without anesthesia (numbing eye drop). The amount of tears produced by the eye in 5 minutes is measured in millimeters by means of a graduated paper scale. Data not reported due to limited number of patients with Schirmer's test data recorded.
|Study Start Date:||January 2009|
|Study Completion Date:||October 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
Patients who received Restasis®
Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
Drug: Cyclosporine Ophthalmic Emulsion 0.05%
One drop two times a day approximately 12 hours apart
Other Name: RESTASIS®
Please refer to this study by its ClinicalTrials.gov identifier: NCT00827255
|United States, Pennsylvania|
|Pittsburgh, Pennsylvania, United States|
|Study Director:||Medical Director||Allergan|